ArticleJournal of thoracic disease2022

A retrospective cohort study of sintilimab and pembrolizumab as first-line treatments for advanced non-small cell lung cancer.

Kai Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.